These are supportive clinical data but not a near-term catalyst, the Phase 3 pediatric studies are still ongoing, and no regulatory filing was announced. The 42% ≥30% LDL-C reduction in CLEAR Outcomes is an incremental positive for the product's on-label messaging. Expect limited stock reaction unless subsequent regulatory news (FDA sNDA filing for pediatric indication) emerges. If you have a position, wait for concrete regulatory milestones.
ESPR drugs
ESPR drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · May 26 $3.12entry
- T+1 · 6mo ago +0.32%α +0.31% · $3.13
- T+5 · 6mo ago +0.32%α −0.76% · $3.13
- T+20 · 5mo ago +0.96%α +2.91% · $3.15
- T+60 · due 3mo ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Esperion presented Phase 2 pediatric data and a CLEAR Outcomes post-hoc analysis at EAS 2026, showing bempedoic acid reduced LDL-C in children (range 6-25%) without new safety concerns, and that 42% of statin-intolerant adults achieved ≥30% LDL-C reduction. These data support ongoing Phase 3 pediatric studies and reinforce the product profile, but are interim scientific presentations without a hard regulatory catalyst or financial update.
Key Facts
- Phase 2 study in children aged 6-17 with HeFH showed weight-based bempedoic acid dosing produced adult-equivalent exposure and LDL-C reductions of 6-25% with no new safety signals.
- CLEAR Outcomes post-hoc analysis: 42% of statin-intolerant adults on bempedoic acid achieved ≥30% LDL-C reduction at 3 months, comparable to moderate-intensity statins.
- Factors associated with ≥30% LDL-C reduction included female sex, higher baseline LDL-C, and concurrent ezetimibe use.
- No new regulatory approvals, label expansions, financial results, or guidance were announced in this press release.
Financial Impact
No financial figures disclosed; data support potential label expansion to pediatric population and commercial differentiation.
Risk Factors
- Phase 3 pediatric study results could differ from Phase 2, delaying or preventing label expansion.
- Competition from newer non-statin LDL-C therapies (e.g., PCSK9 inhibitors, oral siRNA) could pressure commercial adoption.
- Esperion remains dependent on single-drug revenue; a pipeline setback would be disproportionately impactful.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3300994 |
Track record
21 reports on ESPR
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +16.30% at T+60 after the Mar 10, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G/A Bearish 4/10 No price data
- Sep 3, 202610w ago Court Ruling Bullish 5/10 No price data
- Aug 13, 202613w ago Institutional Cluster Bearish 5/10 No price data
- Jul 23, 202616w ago 15-12G Neutral 5/10 No price data
- Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
- Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
- Jul 13, 202618w ago 25-NSE Bullish 7/10 Entry $3.19 No price data
- Jul 13, 202618w ago 8-K Bullish 7/10 Entry $3.19 No price data
- Jun 16, 202621w ago DEFA14A Bullish 6/10 Entry $3.17 No price data
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.15 to $3.19 ▲ +1.27% −0.62% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers